Hospital
Mountain View Hospital, INC.
Mountain View Hospital, INC. was paid $6.14M by Medicaid between Jan 2018 and Nov 2024, across 86 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 82% of everything it billed.
33Billing provider infoMOUNTAIN VIEW HOSPITAL, INC.
PAYSON, UT 84651
PAYSON, UT 84651
33aNPI1487607669assigned 05/18/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.14M
24GClaims112,132
24DCodes billed86
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Utah
Rank by total paid#14 of 26
Median peer was paid$6.14M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,915 | $1.02M | |
| 2019 | 21,991 | $1.01M | |
| 2020 | 23,042 | $1.38M | |
| 2021 | 22,859 | $1.39M | |
| 2022 | 19,129 | $1.23M | |
| 2023 | 1,473 | $80K | |
| 2024incomplete | 723 | $31K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 82% | 17,221 | 7,725 | $5.01M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.0% | 829 | 725 | $182K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.4% | 4,819 | 4,250 | $146K |
| 80053 | Comprehensive metabolic panel | 1.8% | 6,085 | 5,023 | $112K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.8% | 7,039 | 5,851 | $110K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,171 | 947 | $57K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,610 | 1,507 | $54K |
| 81001 | <1% | 5,253 | 4,480 | $44K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,780 | 2,132 | $39K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,017 | 882 | $38K |
| 86710 | <1% | 587 | 547 | $36K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,059 | 973 | $30K |
74 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 2,145 | $27K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,150 | $24K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 95 | $24K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,172 | $20K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 436 | $20K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 524 | $19K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 173 | $19K |
| 99285 | Emergency room visit (most serious) | <1% | 1,632 | $14K |
| 85027 | <1% | 9,239 | $12K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 893 | $7K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,862 | $7K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,296 | $6K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,196 | $6K |
| 83605 | <1% | 2,744 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 48 | $6K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,782 | $6K |
| 84484 | <1% | 1,860 | $4K | |
| 80076 | <1% | 1,968 | $3K | |
| 81025 | <1% | 1,112 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 33 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,805 | $3K |
| 83690 | <1% | 2,742 | $3K | |
| 87077 | <1% | 169 | $3K | |
| 80143 | <1% | 130 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,513 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,082 | $2K |
| 96376 | <1% | 1,535 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 990 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 716 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,577 | $2K |
| 80305 | <1% | 220 | $2K | |
| 84703 | <1% | 1,412 | $2K | |
| 87081 | <1% | 70 | $1K | |
| 82247 | <1% | 25 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 265 | $1K |
| 82550 | <1% | 801 | $1K | |
| 84439 | <1% | 597 | $1K | |
| 85610 | <1% | 109 | $887.49 | |
| 87040 | <1% | 874 | $726.45 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 15 | $723.11 |
| 86140 | <1% | 86 | $614.32 | |
| G0378 | Hospital observation service, per hour | <1% | 531 | $612.12 |
| 86900 | <1% | 87 | $560.81 | |
| 80320 | <1% | 17 | $507.13 | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 16 | $356.81 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 16 | $337.80 |
| 86850 | <1% | 14 | $210.26 | |
| 83880 | <1% | 182 | $200.60 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 73 | $98.65 |
| 85379 | <1% | 336 | $70.08 | |
| 82077 | <1% | 602 | $60.40 | |
| 87186 | <1% | 168 | $42.67 | |
| 97116 | <1% | 28 | $22.60 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 172 | $5.21 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 83 | $0.77 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 89 | $0.67 |
| 80179 | 0% | 115 | $0.00 | |
| 87634 | 0% | 13 | $0.00 | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 0% | 13 | $0.00 |
| 87420 | 0% | 17 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 49 | $0.00 |
| 72125 | Computed tomography, cervical spine; without contrast material | 0% | 24 | $0.00 |
| 99152 | 0% | 58 | $0.00 | |
| 76376 | 0% | 74 | $0.00 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 0% | 16 | $0.00 |
| 97161 | 0% | 13 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 388 | $0.00 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 118 | $0.00 |
| 86901 | 0% | 87 | $0.00 | |
| 36000 | 0% | 59 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 21 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 30 | $0.00 |
| A9270 | Non-covered item or service | 0% | 45 | $0.00 |
| 83735 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHRAMM, STEVEN (CFO)